the clinical use of tyrosine kinase inhibitors in egfr-mutant nsclc
Published 7 months ago • 178 plays • Length 6:15Download video MP4
Download video MP3
Similar videos
-
4:12
ideal treatment duration of tyrosine kinase inhibitors in egfr-mutant nsclc
-
4:09
tyrosine kinase inhibitors in egfr-mutant nsclc: when and who?
-
2:54
pembrolizumab or egfr tyrosine kinase inhibitors in nsclc?
-
0:52
selecting egfr tyrosine kinase inhibitors for egfr-mutant lung cancer
-
2:27
combining egfr and vegf inhibitors for nsclc
-
2:01
checkmate-722: investigating the addition of immunotherapy to chemotherapy in egfr-mutant nsclc
-
13:06
noemi reguart, esmo 2019 - egfr tyrosine kinase inhibitors in nsclc
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
1:18
exploring neoadjuvant egfr-tkis in lung cancer
-
4:37
advances in efgr-mutant nsclc treatment
-
0:48
assessing efgr tkis in patients with wild-type efgr nsclc
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
2:28
clinical trials of neoadjuvant targeted therapy in resectable nsclc
-
1:10
immuno-oncology agents plus tyrosine kinase inhibitors?
-
0:47
mechanisms of resistance to egfr tyrosine kinase inhibitors | rtcl.tv
-
8:41
use of vegf-targeted tyrosine kinase inhibitors
-
2:23
the future of tyrosine kinase inhibitors for melanoma and open questions
-
0:34
mechanisms of resistance to egfr tyrosine kinase inhibitors | rtcl.tv